Wiedenmann

Prof. Bertram Wiedenmann

ENETS Chair from 2004 until 2006

Bertram Wiedenmann is Senior Professor at the Department of Hepatology and Gastroenterology at Charité Medical School in Berlin, Germany and was head of the department until 2019. His major research interests comprise molecular and cell biology involving especially cellular signal transduction pathways in the field of gastrointestinal oncology.

Prof. Wiedenmann received his M.D. from the Technical University of Munich Medical School in 1980. He completed a Fulbright Research Fellowship in haematology at the Albert Einstein College of Medicine, NY, USA (1980-1982), was a Research Associate in Cell Biology at the Biological Laboratories, Harvard University (1982-1983), and at the German Cancer Research Center, Heidelberg, Germany (1983-1984). In 2008 he founded 3B Pharmaceuticals, the now successful radiopharmaceutical Berlin company, which, among other things, is currently developing a radiopharmaceutical for the treatment of neuroendocrine neoplasia. Prof. Wiedenmann was chair of ASCO-GI in 2017 and is currently CMO of AutemTherapeutics, an American start-up company developing a novel oncological device. He is a member of several international and national societies, such as AGA, ASCO, and ESMO. He is the former chairman and long-term treasurer of the European Neuroendocrine Tumor Society (ENETS), former member of the steering committee of the Comprehensive Cancer Center Charité, and former coordinator of the site management organisation (SMO) for clinical studies (KKS Charité) at the Charité Medical School.

At the German Cancer Center, Heidelberg, Germany, Prof. Wiedenmann - together with Werner Franke - discovered the well-known tumor marker Synaptophysin. In addition to seven publications in Nature and its daughter journals, he has published more than 1,000 peer-reviewed papers and is a reviewer for many international and national journals.

Back to All Chairs